cyrilzakka/clinical-trials huggingface dataset:
Collection and Banking of Leukemia Cells MDS/AML

The goal of this research study is to determine if it is feasible to collect leukemia cells from patients ahead of time (before they undergo further treatments) so that these cells (after being radiated so they will no longer grow or divide) can be given back to them as a cancer vaccine if/after the participant receives a bone marrow or blood stem cell transplant in the future. The purpose of the research study will be to collect, freeze and store leukemia calls from participants blood or bone marrow. This study is a companion study to a vaccine study.

* Leukemia cells will be collected by one or more of the following methods: 1)Routine blood draw 2)Bone marrow aspirate 3) Leukapheresis. The physician and study staff will determine which of the methods above is best suited for each participant.
* After collection, the leukemia cells will be transported to the Cell Manipulation Core Facility (CMCF) at the Dana-Farber Cancer Institute, where they will be frozen until the time of vaccine administration.

Eligibility Criteria:
Inclusion Criteria:

* Patients with AML will be eligible for banking at the time of relapse or primary induction failure or at the time of AML diagnosis they are 60 years of age or older, AML arising out of background MDS or MPD or AML known with high risk cytogenetics
* Patients with MDS-RAEB-1 or RAEB-II, CMML-1 or CMML-II
* Patients must have \>5% blast in bone marrow or peripheral blood
* ECOG Performance Status 0-2
* Age greater than or equal to 18 years
* Reasonable likelihood, in the physician's opinion, that the patient will be a candidate for allogeneic stem cell transplant
Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures

The purpose of this study is to compare the cosmetic outcome between buried intradermal and superficial cutaneous suture closures versus buried intradermal sutureand superficial Steri-Strip closures in the bilayered repair of dermatologic wounds on the back following elliptical excision of benign or malignant lesions


Eligibility Criteria:
Inclusion Criteria:

* 18 years or greater in age
* Simple excision of benign or malignant lesion on the back
* Final scar length of at least 3cm

Exclusion Criteria:

* Known history of keloid formation or hypertrophic scars
* Known adhesive allergy
* Pregnancy or active breast feeding
Neo-TACE-HAIC for PVTT-HCC

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for treatments. Although BCLC (Barcelona clinical liver cancer) system recommend to palliative targeted treatment, the East Asian countries recommend to resection or transartery chemoembolization (TACE).

Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC.

Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.

Whether TACE-HAIC would improve survival for patients with PVTT is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-75 years;
* Patients with resectable primary hepatocellular carcinoma and portal vein tumor thrombus, which was not located in main portal vein;
* Child-Pugh A or B (7 score) liver function;
* With more than 3 months expected survival;
* The volume of residual liver more than 30%

Exclusion Criteria:

* Patients with primary hepatocellular carcinoma and major portal vein tumor thrombus
* With extrahepatic metastasis or unresectable HCC
* Pregnant woman or sucking period;
* With other malignant cancer;
* Received chemotherapy, target therapy or immunosuppressive drugs therapy before this study.
Food at Home Study

The study objective is to develop an accessible home food environment assessment toolkit that includes valid and reliable paper and electronic tools targeting foods known to impact diet-related health that can be user-administered across literacy levels in English and Spanish.


Eligibility Criteria:
Inclusion Criteria:

* Speak Spanish or English at home
* 18 or older
* primary grocery shopper or meal preparer

Exclusion Criteria:

* Any person younger than 18
* lacks the capacity to consent
* does not purchase the majority of the groceries for the home
The Use of Chinese Herbal Medicine and Vitamin C by Hospital Care Workers in HK to Prevent COVID-19

This is a prospective randomized controlled trial study to explore whether the combination of Chinese herbal medicine and Vitamin C is effective and safe to prevent COVID-19 transmission among health care workers in Hong Kong Mobile Cabin Hospital governed by the Hong Kong Hospital Authority who have been caring for patients with COVID-19. A total of 652 adults will be enrolled. Eligible subjects who provide written informed consent will be assessed for inclusion/exclusion criteria.

All participants are asymptomatic and test negative for SARS-CoV-2 at the study's commencement. Subjects with major medical illness, renal insufficiency and hypersensitivity to Chinese herbal medicine will be excluded. All participants will receive Vitamin C (VC) supplementation and 28 packets of the herbal medicine free of charge and are advised to consume daily for 14 days. After written informed consent, the subjects will be included and randomly allocated to either CHM+VC group or VC treatment.


Eligibility Criteria:
Inclusion Criteria:

1. Health care workers in Hong Kong Mobile Cabin Hospital;
2. Asymptomatic and test negative for SARS-CoV-2;
3. Aged ≥18;
4. Voluntarily signing a written informed consent form;

Exclusion Criteria:

1. With major medical illness or renal insufficiency;
2. With hypersensitivity to Chinese herbal medicine;
3. Pregnancy or lactation.
Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy

The aim of the study was to evaluate a new integrative day-care clinic concept for breast cancer patients receiving chemotherapy. This is an explorative pilot study. Therefore, all outcomes are analyzed exploratively.


Eligibility Criteria:
Inclusion Criteria:

* curative malignancy (breast cancer of TNM (T: primary tumor, N: regional nodes, M: metastasis) staging I-III)
* receiving chemotherapy
* at least 18 years old
* written informed consent
* willing and physically/mentally able to participate in a six hours day care clinic program eleven times during chemotherapy.

Exclusion Criteria:

* insufficient knowledge of the German language
* physical or mental disabilities resulting in ineligibility for participation in the program or filling out the questionnaires.
Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants

The purpose of this study is to determine the survival rate, marginal bone resorption, soft tissue health and maintenance of the NobelActive Internal and External implants and to make comparisons with the NobelReplace Tapered Groovy implant placed in healed sites.

The purpose of this study is to determine safety and efficacy parameters for the NobelActive Internal and External implants and to make comparisons with the NobelReplace Tapered Groovy implant placed in healed sites.

Safety: AEs

Efficacy:

* survival rates,
* marginal bone resorption with marginal bone levels measurement,
* soft tissue health and maintenance via gingival index measurement, plaque index, papilla index .

Eligibility Criteria:
Inclusion Criteria:

* The subject should be in need of an implant supported fixed restoration
* The subjects should have sufficient bone volume and density i.e. an osseous architecture in the planned implant placement region sufficient to receive implants with a diameter of 3.5 mm and a length of at least 10 mm.
* The subject as well as the implant sites should fulfill criteria for immediate functional tem-porization within 24 h.
* The implant sites should be healed and free from infection.

Exclusion Criteria:

* Alcohol or drug abuse as noted in patient records or in patient history.
* Health conditions, which do not permit the surgical procedure.
* Reason to believe that the treatment might have a negative effect on the subject's total situation (psychiatric problems), as noted in patient records or in patient history.
* The subject is not able to give her/his informed consent to participate.
* The need of bone augmentation before implant installation to obtain a prosthetically correct implantation transversally. However, a minor augmentation procedure to cover exposed threads or interproximal / buccal grafting due to deficient sites is not an exclusion criteria.
* Any disorders in the planned implant area such as previous tumors, chronic bone disease, or previous irradiation.
* Uncontrolled diabetics will be excluded.
* Severe bruxism or other destructive habits.
* Immediate insertion (e.g. placement of the implant immediately after extraction) consti-tutes an exclusion criterion.
Obstetricians' Views on the Reasons for Egypt's High Caesarean Section Rates

Handling of questionnaires to a number of obstetricians from different hospitals to show their perceptions about causes of high cs rate in Egypt

An open-ended self-administered questionnaire Handled to a number of obstetricians from different hospitals to show their perceptions about causes of the high cs rate in Egypt.

Eligibility Criteria:
Inclusion Criteria:

Obstetricians from different hospitals. -

Exclusion Criteria:

Refusal to participate

-
Cryoablation of AF: Improving the Use of the Achieve Catheter

According to data from high volume Centres, documentation of entry block with the Achieve catheter may be possible in only about to 50% of pulmonary veins. The investigators aim to assess strategies using the Achieve catheter that can improve this performance.


Eligibility Criteria:
Inclusion Criteria:

* all consecutive patients undergoing atrial fibrillation cryoballoon ablation monitored with the Achieve catheter.

Exclusion Criteria:

* patients in AF at the beginning of the procedure
* patients with a previous AF ablation procedure
Italian NCL Registry: a Registry for NCL As an Integration Tool for Future Therapeutic Strategies

The goal is to create a solid and harmonious disease registry of patient affected by neuronal ceroid lipofuscinosis (NCLs) that facilitates the collection and management of patients' data over time encouraging the research and the development of future clinical trials. In-depth clinical phenotyping will develop significant clinical outcome measures that can be used in clinical trials and will allow the phenotypic complexity of the disease to be captured with the use of validated clinical scales, biomarkers and so-called patient reported outcomes (PROs).

The registry will involve three recruiting clinical centres (IRCCS Fondazione Stella Maris in Pisa, Ospedale pediatrico Bambin Gesù in Roma e IRCCS Istituto Neurologico Carlo Besta in Milano). Participants will be assessed annually at one of the three participating clinical sites. For each patient, at least one follow-up visit will be scheduled at an interval of 12 months in order to monitor and compare the longitudinal progression of NCLs in similar groups (for example based on phenotype, age at onset, or genotype). At each visit all enrolled subjects will carry out a clinical-instrumental evaluation as per clinical practice, including: anamnestic collection, general and neurological objective examination; administration of illness scales (e.g. the Hamburg scale, UBDRS) and questionnaires about psychiatric symptoms, sleep disorders and quality of life. Any biological samples will be collected as tissues, blood or urine and stored in the laboratories or bio-repositories of the individual centers and also reported in the electronic clinical report form (CRF) of NCL Registry. The results of further diagnostic tests carried out such as Optical coherence tomography (OCT), brain magnetic resonance imaging (MRI) or neurophysiology performed during diagnostic practice or clinical follow up will also be collected. Any further clinical scales/evaluation questionnaires to be administered will be selected according to clinical need based on the neurological characteristics and genotype of each participant. All data relating to further instrumental and/or neurophysiological investigations carried out by the patient for clinical needs will also be collected.

The data collected during the aforementioned clinical-instrumental-laboratory evaluations will be entered into the Italian NCL registry in pseudonymized form.

Eligibility Criteria:
Inclusion Criteria:

* genetically confirmed diagnosis of neuronal ceroid lipofuscinosis
* participants/parents/legal guardians will have to give informed consent for enrollment in the registry and privacy data management

Exclusion Criteria:

* subjects affected by other forms of neurodegenerative diseases.
* lack of informed consent
Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection

This study intends to collect the clinical data of patients with Helicobacter pylori infection, and to observe and count the high-dose double therapy and the traditional quadruple / triple therapy ( i.e., esomeprazole + amoxicillin double high-dose double therapy and esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate traditional quadruple therapy or Vonoprazan + amoxicillin double high-dose double therapy and Vonoprazan + amoxicillin + clarithromycin triple therapy ). The eradication rate of Helicobacter pylori was compared between the two different regimens respectively, and the efficacy, safety and compliance of different regimens were compared. It provides a new reference for clinical treatment of Helicobacter pylori, and has great clinical value and significance for simplifying the anti-Helicobacter-pylori treatment plan, increasing patient compliance, and exploring efficient anti-Helicobacter-pylori therapy suitable for the Chinese population.


Eligibility Criteria:
Inclusion Criteria:

1. patients aged 14-90 years, no requirement for gender;
2. patients diagnosed as H. pylori infection by at least one of the following tests: carbon-13/14 urea breath test (13C/14C-UBT) or immuno-histochemical staining of biopsy specimens;
3. patients with no use of antibiotics, bismuth or Chinese traditional medicines with antibacterial effects in the previous 4 weeks of 13C/14C-UBT, and no H2 receptor antagonists, PPIs, P-CAB or other drugs affecting H .pylori activity within the previous 2 weeks of 13C/14C-UBT;
4. patients without history of receiving H. pylori eradication therapy.

Exclusion Criteria:

1. patients with serious diseases or clinical conditions that may interfere with the evaluation of the results of the study, such as severe heart, liver, lung, and renal insufficiency, low immunity, and so on;
2. patients with allergy to penicillin or any research-program-related drugs;
3. patients with mental illness and communication disorders;
4. patients in pregnancy or lactation;
5. patients with severe gastrointestinal diseases, such as gastrointestinal tumors, gastrointestinal bleeding, other organic diseases, etc.;
6. patients who were participating in other clinical trials;
7. patients who were considered inappropriate for enrollment after evaluation by the researchers.
Colonoscopy and Antiplatelet Therapy Trial

Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 45 years
2. Stable patients defined as having Angina CCS (Canadian Cardiovascular Society) class 1-3 and/or Heart Failure NYHA class 1-2 without a change in guideline directed anti-ischemic or heart failure medications within 30 days prior to randomization.
3. Patients with cardiovascular disease defined as coronary artery disease, cerebrovascular disease or peripheral vascular disease taking DAPT (defined as aspirin plus a P2Y12 inhibitor). The decision to use DAPT in this patient will be made by the managing physician(s) before recruitment for this study. Consider replacing last statement with "As directed by their physician prior to recruitment into this study"
4. Scheduled for elective screening or surveillance outpatient colonoscopy

Exclusion Criteria:

1. Coronary intervention (PCI or CABG) less than 90 days prior to randomization
2. ACS event in less than 90 days prior to randomization
3. Transient ischemic attack (TIA) and/or stroke event in less than 90 days prior to randomization
4. Acute limb ischemia and/or amputation in less than 90 days prior to randomization
5. Post cardiac valve replacement (either percutaneous or surgical)
6. High cardiovascular risk:

   1. Patients with CCS class 4 angina
   2. Hospitalized with ACS within 1 month prior to randomization
   3. Patients undergoing PCI or CABG within the 3 months prior to randomization
7. Patients on left ventricular assist device (LVAD) or post cardiac transplantation
8. Patients with NYHA class 3 or 4 heart failure
9. Any condition requiring treatment requires chronic use of an anticoagulant.
10. Chronic kidney disease Stage 5 (with or without dialysis)
11. Liver cirrhosis with platelet count \&lt; 50,000/ mm3 and/or INR \&gt;1.4
12. Hematocrit \&lt; 30% and hemoglobin \&lt; 10 mg/dL
13. Emergent or inpatient Colonoscopy
Diazepam and Blood Pressure Regulation

The aim of this study is to determine the acute effects of diazepam on beat-to-beat blood pressure variability and baroreflex control.

Benzodiazepines are widely prescribed for a variety of clinical conditions. However, its cardiovascular consequences remain controversial. In this study, the investigators sought to determine the acute effects of a single dose of oral diazepam (10mg) on resting beat-to-beat blood pressure variability and cardiac and sympathetic baroreflex sensitivity in a cohort of young, healthy individuals.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 40 years of age
* Healthy, free of known cardiovascular, metabolic, or musculoskeletal disease

Exclusion Criteria:

* History of smoking (tobacco or cannabis), defined as any smoking within the past 3 months
* Diagnosed cardiovascular or metabolic disease(s)
* Prescription of chronic medications other than oral contraceptives
* History of hypertension or presence of arrhythmia
Risk Markers of Arterial Aging. The Paris Prospective Study III-2

The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.

Since May 2008, PPS3 is being following the CVD morbidity of 10157 healthy volunteers aged 50-75 years at baseline. In PPS3-2, we plan to re-invite survivors and volunteers of PPS3 to undergo a second physical examination. In particular, they will undergo a second high-precision carotid echotracking to measure vascular aging parameters and baroreflex sensitivity, permitting to study their respective dynamics. They will also underwent for the first time ultra fast echo of the radial artery to measure vascular aging parameters of the medium-sized arteries. According to fundings, blood samples will be taken and stored at -80°C in the whole population or in a subsample.

Eligibility Criteria:
Inclusion Criteria:

* Being enrolled in PPS3 and having signed an informed consent for PPS3-2

Exclusion Criteria:

* Institutionalized participants
* Participants under guardianship
* Participants under judicial safeguard measure
Modified Allen's Test and Peripheral Perfusion Index

to detect the relation between results of the peripheral perfusion index and modified Allen's test.

The modified Allen's test (MAT) is commonly used to assess hand perfusion. Other non-invasive methods including plethysmography, pulse oximetry and duplex ultrasonography are used nowadays. The perfusion index is calculated as the ratio of the pulsatile blood flow to non- pulsatile blood flow in peripheral tissue.

In this study, we will try to detect the relation between results of the peripheral perfusion index and modified Allen's test.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients or healthy volunteers

Exclusion Criteria:

-
Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus

The purpose of this study is to determine if daily supplementation with 2000 International Units of Vitamin D will improve hemoglobin A1c in uncontrolled type 2 diabetics.

Vitamin D is typically understood to support musculoskeletal health when administered concomitantly with calcium. A number of recent studies suggest, however, that this important nutrient may play a significant role in many pathophysiological processes, including diabetes mellitus. With the prevalence of diabetes mellitus ever increasing, novel mechanisms for controlling blood glucose and hemoglobin A1c are being sought to help prevent the costly and debilitating complications of this chronic disease.

Eligibility Criteria:
Inclusion Criteria:

* Type 2 diabetes mellitus
* Hemoglobin A1c \>7% measured in the 3 months prior to randomization
* Age 21 to 75 years

Exclusion Criteria:

* Renal insufficiency (defined as CrCl \<30mL/min)
* Gestational diabetes
* Malabsorption syndrome
* Patients taking vitamin D supplements at doses \>400 international units daily
Antenatal Corticoid Therapy for Late Preterm Babies

This study aims to determine the effectiveness of antenatal corticosteroid therapy in late preterm babies. The investigators hypothesis is corticoid accelerates fetal lung maturation even after 34 weeks and reduces risk of respiratory distress syndrome and other neonatal morbidities.

Late preterm babies have important morbidity when compared with term babies, with oxygen requirement and more days of hospitalization. If antenatal corticosteroid therapy is necessary for fetal lung maturation after 34 weeks, it remains to be established. The systematic review with metanalysis in Cochrane Library includes a small number of late preterm babies and no conclusion about effectiveness of corticoid therapy in this setting could be drawn. Our hypothesis is that antenatal corticosteroid therapy is effective to prevent respiratory disease and morbidity in late preterm babies and this study will be carried out to evaluate this question.

Eligibility Criteria:
Inclusion Criteria:

* Pregnancy between 34 and 36 weeks
* Confirmed gestational age (LMP, USG)
* Alive fetus
* Imminent risk of preterm delivery

Exclusion Criteria:

* Multiple pregnancy
* Major fetal malformations
* Comproved fetal lung maturity
* Maternal or fetal indication for immediate interruption of pregnancy
* Maternal hemorrhagic syndromes (placenta previa, abruptio placenta)
* Chorioamnionitis
* Chronic use of corticosteroids
* Previous use of corticosteroids for fetal lung maturation in the current pregnancy